Loading...
Loading...
AMRN| Name | Value |
|---|---|
| Revenues | 90.2M |
| Cost of Revenue | 26.6M |
| Gross Profit | 63.6M |
| Operating Expense | 73.4M |
| Operating I/L | -9.8M |
| Other Income/Expense | 3.0M |
| Interest Income | 1.6M |
| Pretax | -6.8M |
| Income Tax Expense | -7.6M |
| Net Income/Loss | 0.9M |
Amarin Corporation plc is a pharmaceutical company specializing in the development and commercialization of therapeutics for cardiovascular diseases. Its primary product, VASCEPA, is a prescription omega-3 fatty acid used to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The company generates revenue by selling its products to wholesalers and specialty pharmacy providers. Additionally, it has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in VASCEPA. Amarin Corporation plc, formerly known as Ethical Holdings plc, was incorporated in 1989.
